Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
Funding Opportunity PAR-20-314 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated i...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 13, 2020 Category: Research Source Type: funding
Utilizing In Vitro Functional Genomics Advances for Gene-Environment (G x E) Discovery and Validation (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-ES-20-018 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to fully integrate recent innovative advances of in vitro functional genomics tools/technologies and approaches for environmental health and toxicology applications. The overall goal of this NIEHS led initiative is to generate proof-of-principle studies incorporating these new in vitro approaches, together with well characterized exposures, to further our understanding of gene-environment (G x E) interactions in complex human disorders. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 13, 2020 Category: Research Source Type: funding
Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)
Funding Opportunity RFA-ES-20-014 from the NIH Guide for Grants and Contracts. The National Institute of Environmental Health Sciences (NIEHS) is announcing the continuation of the Superfund Hazardous Substance Research and Training Program, referred to as Superfund Research Program (SRP) Centers. SRP Center grants will support problem-based, solution-oriented research Centers that consist of multiple, integrated projects representing both the biomedical and environmental science and engineering disciplines; as well as cores tasked with administrative (which includes research translation), data management and analysis, ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 2, 2020 Category: Research Source Type: funding
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
Funding Opportunity PAR-20-292 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical tr...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 24, 2020 Category: Research Source Type: funding
Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-20-253 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for NIH Countermeasures Against Chemical Threats (CounterACT) exploratory/developmental (R21) projects. The mission of the NIH CounterACT program is to foster and support research that will advance development of new and improved therapeutics to mitigate the health effects of chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical wa...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 7, 2020 Category: Research Source Type: funding
Preclinical Development of Novel Therapeutics Targeting Aging Mechanisms (SBIR U44 Clinical Trial Not Allowed)
Funding Opportunity RFA-AG-21-026 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) utilizes the SBIR cooperative agreement (U44) activity code to support the preclinical development of emerging therapeutics targeting fundamental mechanisms of aging (e.g., inflammation, cell senescence, proteostasis). This includes the translation of a broad range of potential geroscience-based therapies, such as new classes of compounds (e.g., senolytics), biologics, stem/progenitor cell-based therapies, repositioning of existing investigational drugs, and repurposing of Food and Drug Administrati...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 25, 2020 Category: Research Source Type: funding
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
Funding Opportunity PAR-20-111 from the NIH Guide for Grants and Contracts. Reissue of PAR-18-541. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project w...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 3, 2020 Category: Research Source Type: funding
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
Funding Opportunity PAR-20-122 from the NIH Guide for Grants and Contracts. Reissue of PAR-18-546. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their pr...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 3, 2020 Category: Research Source Type: funding
HEAL Initiative: Pharmacotherapies to Reverse Opioid Overdose Induced Respiratory Depression without Central Opioid Withdrawal (Target Validation and Candidate Therapeutic Development (R61/R33 - Clinical Trial Not Allowed)
Funding Opportunity RFA-HL-20-031 from the NIH Guide for Grants and Contracts. This FOA invites applications for pre-clinical research to stimulate the development of novel, mechanism-based pharmacotherapies to selectively reverse breathing suppression produced by opioids. Two critical phases of pre-clinical investigation are supported. Phase I: the identification and rigorous validation of candidate targets; Phase II: development of therapeutic candidates, such as small molecules, biologics, and natural products that modulate validated targets identified in Phase I, using relevant animal models or human cells/tissue. S...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 24, 2020 Category: Research Source Type: funding
Immune Tolerance Network (UM1 Clinical Trial Required)
Funding Opportunity RFA-AI-19-068 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Immune Tolerance Network. The major goal of this Network is to develop tolerogenic approaches for the treatment and prevention of disease in three clinical areas: asthma and allergic diseases; autoimmune diseases; and immune-mediated consequences of allotransplantation. The scope of research to be carried out includes: 1) the design and conduct of clinical trials at all phases to evaluate the safety and efficacy of investigational products and approa...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 6, 2019 Category: Research Source Type: funding
New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed)
Funding Opportunity RFA-ES-20-008 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports Phase I (R43), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant proposals from small businesses concerns (SBCs) to develop resources and approaches, including panels of cells or model organisms, that can better reflect the variability in human populations in chemical toxicity testing. Current toxicology testing is often limited to studies conducted in a small number of laboratory rodent strains, which can fail to identify clinically relevant tox...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 27, 2019 Category: Research Source Type: funding
Organotypic Culture Models developed from Experimental Animals for Chemical Toxicity Screening (R43/R44 Clinical Trial Not Allowed)
Funding Opportunity RFA-ES-20-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports Phase I (R43), Phase II (R44), Direct Phase II (R44) and Fast Track (R44) Small Business Innovative Research (SBIR) grant proposals from small businesses concerns (SBCs) to develop novel, physiologically-relevant in vitro screening systems (e.g., engineered 3-dimensional or organotypic models) using cells derived from animal species typically utilized for toxicological testing, which will replicate biological interactions and toxicological responses observed in animal tissues or organs, wil...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 10, 2019 Category: Research Source Type: funding
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
Funding Opportunity PAR-19-356 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical tr...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 28, 2019 Category: Research Source Type: funding
Partnership to Promote Local Efforts To Reduce Environmental Exposure
Grants to build community capacity to assess and respond to site-specific issues involving human exposure to hazardous substances in the environment. Geographic coverage: Nationwide -- Agency for Toxic Substances and Disease Registry, Centers for Disease Control and Prevention (Source: Funding opportunities via the Rural Health Information Hub)
Source: Funding opportunities via the Rural Health Information Hub - August 26, 2019 Category: American Health Source Type: funding
Biological Testing Facility Access For Contraceptive Development (X01 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-263 from the NIH Guide for Grants and Contracts. The NICHD has a state-of-the art Biological Testing Facility for advancing male and/or female non-hormonal contraception development with the capabilities and capacity for preclinical and Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies (e.g., fertility studies, pharmacology, toxicology, reproductive tract histopathology, sperm morphology). The purpose of this FOA is to provide investigators with a mechanism to request services from this facility that would advance their contraceptive development program....
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 1, 2019 Category: Research Source Type: funding
